We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal
Read MoreHide Full Article
Incyte (INCY - Free Report) , Xencor (XNCR - Free Report) and German company MorphoSys AG (MOR - Free Report) entered into a clinical collaboration deal to evaluate the combination of Monjuvi (tafasitamab), plamotamab and Bristol-Myers’ (BMY - Free Report) Revlimid (lenalidomide) in various lymphoma indications.
Shares of Incyte have lost 5.2% year to date compared with the industry’s decline of 1.7%.
Monjuvi, a CD19-directed antibody, is co-marketed by MorphoSys and Incytein combination with Revlimidfor relapsed or refractory diffuse large B-cell lymphoma (DLBCL).In August 2020, the FDA approved Monjuvi (tafasitamab-cxix) in combination with Revlimid for the treatment of adult patients with relapsed or refractory DLBCL. It is the first FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, addressing a high unmet medical need.
Plamotamab is Xencor’sCD20 x CD3 XmAb bispecific antibody,which is currently in a phase I study for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It has shown encouraging clinical activity as a monotherapy in NHL.
Per the agreement, the companies plan to initiate a phase I/II study evaluating the combination of Monjuvi, plamotamab (XmAb 13676) and Revlimid in patients with relapsed or refractory DLBCL. Further, the companies will evaluate the combination in relapsed or refractory FL and first-line DLBCL in multiple phase Ib studies.
We remind investors that MorphoSys and Incyte entered into a collaboration and licensing agreement in January 2020 to develop and commercialize Monjuvi globally. Monjuvi is co-commercialized by Incyte and MorphoSys in the United States, while the former has exclusive commercialization rights outside the United States.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year. These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal
Incyte (INCY - Free Report) , Xencor (XNCR - Free Report) and German company MorphoSys AG (MOR - Free Report) entered into a clinical collaboration deal to evaluate the combination of Monjuvi (tafasitamab), plamotamab and Bristol-Myers’ (BMY - Free Report) Revlimid (lenalidomide) in various lymphoma indications.
Shares of Incyte have lost 5.2% year to date compared with the industry’s decline of 1.7%.
Monjuvi, a CD19-directed antibody, is co-marketed by MorphoSys and Incytein combination with Revlimidfor relapsed or refractory diffuse large B-cell lymphoma (DLBCL).In August 2020, the FDA approved Monjuvi (tafasitamab-cxix) in combination with Revlimid for the treatment of adult patients with relapsed or refractory DLBCL. It is the first FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, addressing a high unmet medical need.
Plamotamab is Xencor’sCD20 x CD3 XmAb bispecific antibody,which is currently in a phase I study for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It has shown encouraging clinical activity as a monotherapy in NHL.
Per the agreement, the companies plan to initiate a phase I/II study evaluating the combination of Monjuvi, plamotamab (XmAb 13676) and Revlimid in patients with relapsed or refractory DLBCL. Further, the companies will evaluate the combination in relapsed or refractory FL and first-line DLBCL in multiple phase Ib studies.
We remind investors that MorphoSys and Incyte entered into a collaboration and licensing agreement in January 2020 to develop and commercialize Monjuvi globally. Monjuvi is co-commercialized by Incyte and MorphoSys in the United States, while the former has exclusive commercialization rights outside the United States.
Incyte currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Incyte Corporation Price
Incyte Corporation price | Incyte Corporation Quote
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year. These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>